CD274 and non-small cell lung carcinoma: In the phase III clinical trial (NCT03631706) using either M7824 or pembrolizumab as first-line treatment for patients with advanced PD-L1 high-expression (TPS ≥80%) NSCLC, the results showed that first-line treatment with M7824 did not demonstrate superior efficacy compared to pembrolizumab and had a higher frequency of associated adverse events (170).